ANI Pharmaceuticals Inc (ANIP) : Healthcare Value Capital reduced its stake in ANI Pharmaceuticals Inc by 12.66% during the most recent quarter end. The investment management company now holds a total of 345,000 shares of ANI Pharmaceuticals Inc which is valued at $24,005,100 after selling 50,000 shares in ANI Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.ANI Pharmaceuticals Inc makes up approximately 37.85% of Healthcare Value Capital’s portfolio.
Other Hedge Funds, Including , Panagora Asset Management Inc reduced its stake in ANIP by selling 1,216 shares or 12.55% in the most recent quarter. The Hedge Fund company now holds 8,476 shares of ANIP which is valued at $589,760.Tiaa Cref Investment Management boosted its stake in ANIP in the latest quarter, The investment management firm added 659 additional shares and now holds a total of 25,631 shares of ANI Pharmaceuticals Inc which is valued at $1,783,405.Blackrock Institutional Trust Company N.a. reduced its stake in ANIP by selling 1,831 shares or 0.96% in the most recent quarter. The Hedge Fund company now holds 189,176 shares of ANIP which is valued at $13,162,866.Blackrock Fund Advisors boosted its stake in ANIP in the latest quarter, The investment management firm added 13,093 additional shares and now holds a total of 660,831 shares of ANI Pharmaceuticals Inc which is valued at $45,980,621. ANI Pharmaceuticals Inc makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Strs Ohio boosted its stake in ANIP in the latest quarter, The investment management firm added 900 additional shares and now holds a total of 12,100 shares of ANI Pharmaceuticals Inc which is valued at $728,299.
ANI Pharmaceuticals Inc opened for trading at $59.63 and hit $63 on the upside on Thursday, eventually ending the session at $61.42, with a gain of 2.81% or 1.68 points. The heightened volatility saw the trading volume jump to 5,70,217 shares. Company has a market cap of $708 M.
On the company’s financial health, ANI Pharmaceuticals Inc reported $1.11 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $0.77. The company had revenue of $31.30 million for the quarter, compared to analysts expectations of $27.63 million. The company’s revenue was up 60.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.55 EPS.
Many Wall Street Analysts have commented on ANI Pharmaceuticals Inc. Raymond James Initiated ANI Pharmaceuticals Inc on Jun 23, 2016 to “Strong Buy”, Price Target of the shares are set at $68.ANI Pharmaceuticals Inc was Downgraded by Standpoint Research to ” Hold” on May 24, 2016.
ANI Pharmaceuticals Inc. (ANI) is an integrated specialty pharmaceutical company engaged in developing manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include narcotics oncolytics (anti-cancers) hormones and steroids and complex formulations involving release and combination products. The Company has two pharmaceutical manufacturing facilities located in Baudette Minnesota that are capable of producing oral solid dose products as well as liquids and topicals narcotics and potent products. The Company’s branded products consist of Cortenema Lithobid Reglan and Vancocin. Its generic products include Esterified Estrogen with Methyltestosterone Fluvoxamine Maleate Hydrocortisone Enema Methazolamide Metoclopramide and Opium Tincture. The Company’s markets include hormone and steroidal drugs oncolytics and narcotics and complex formulations including extended release and combination products.